RAVELLI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 161
EU - Europa 118
AS - Asia 70
Totale 349
Nazione #
US - Stati Uniti d'America 160
CN - Cina 38
IT - Italia 36
IE - Irlanda 34
SG - Singapore 22
SE - Svezia 16
CZ - Repubblica Ceca 7
DE - Germania 7
AT - Austria 5
FR - Francia 4
TR - Turchia 4
BE - Belgio 3
FI - Finlandia 2
JP - Giappone 2
AE - Emirati Arabi Uniti 1
CA - Canada 1
GB - Regno Unito 1
IN - India 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
NL - Olanda 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 349
Città #
Dublin 34
Chandler 31
Parma 20
Singapore 17
Dearborn 13
Ann Arbor 11
New York 10
Ashburn 7
Nanjing 7
Shanghai 7
Boardman 6
Brno 6
Shenyang 6
Princeton 5
Vienna 5
Izmir 4
Redmond 4
Bremen 3
Brussels 3
Norwalk 3
San Mateo 3
Fuzhou 2
Hebei 2
Hefei 2
Los Angeles 2
Seattle 2
Wilmington 2
Woodbridge 2
Bacoli 1
Beijing 1
Cagliari 1
Changsha 1
Dubai 1
Fremont 1
Guangzhou 1
Helsinki 1
Houston 1
Huizen 1
Jinan 1
Kunming 1
Mumbai 1
Munich 1
Nanchang 1
Redwood City 1
Saint Petersburg 1
Santa Clara 1
Scottsdale 1
Seoul 1
Taizhou 1
Tianjin 1
Torino 1
Vancouver 1
Vientiane 1
Wenzhou 1
Totale 245
Nome #
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 92
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 78
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 76
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 68
CDK4/6 inhibitors in HER2-positive breast cancer 57
Totale 371
Categoria #
all - tutte 1.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.495


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202038 0 0 0 0 3 9 16 1 4 2 3 0
2020/202112 0 0 0 0 5 1 0 1 0 2 3 0
2021/202219 0 0 0 1 0 0 5 2 0 2 0 9
2022/2023125 10 15 10 10 7 13 0 7 42 0 9 2
2023/202452 4 3 1 1 5 14 5 0 1 3 4 11
2024/202531 1 5 7 10 8 0 0 0 0 0 0 0
Totale 371